RxDoctor Payments Data

Michael Black, MD

Family Medicine · Poland, OHNPI 1497730857

Payments from drug & device makers

$8,525in general payments, 2019–2025

Across 574 payments — averaging $14.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • AstraZeneca$746
  • Amgen$668
  • Merck$587
  • Amarin Pharma, Inc.$550
  • Novo Nordisk$420
  • plus $4K from 54 others

What the payments were for

  • Food & beverage$8,47199%
  • Education$541%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)85$1,219
AstraZeneca41$746
Amgen46$668
Merck44$587
Amarin Pharma, Inc.43$550
Novo Nordisk32$420
Pfizer23$330
Teva Pharmaceuticals USA, Inc.22$297
Corium, LLC19$262
Boehringer Ingelheim15$253
Johnson & Johnson16$235
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC14$220
Corcept Therapeutics8$162
Abbott9$138
Dexcom, Inc.6$121
Regeneron Healthcare Solutions, Inc.6$109
Lilly USA, LLC7$106
Takeda Pharmaceuticals U.S.A., Inc.10$98
Biohaven Pharmaceutical Holding Company Ltd.6$97
Otsuka America Pharmaceutical, Inc.6$91
Kowa Pharmaceuticals America, Inc.6$90
Exact Sciences4$83
Novartis5$78
Jazz Pharmaceuticals Inc.4$77
Axsome Therapeutics, Inc.4$73
Shield Therapeutics Inc4$66
Mylan Specialty L.p.4$66
Sanofi Pasteur Inc.4$66
Romark Laboratories, LC5$63
Sanofi-aventis U.S. LLC5$62
GSK3$61
Esperion Therapeutics, Inc.4$59
Tris Pharma Inc3$56
Nestle Healthcare Nutrition Inc.4$55
Neos Therapeutics, LP3$54
Astellas Pharma US Inc3$54
Ironshore Pharmaceuticals Inc.3$46
E.r. Squibb & Sons, L.L.C.3$39
Supernus Pharmaceuticals, Inc.2$33
Avanir Pharmaceuticals, Inc.2$32
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)2$32
Eisai Inc.2$31
IBSA Pharma Inc.2$31
Seqirus USA Inc2$30
Vanda Pharmaceuticals Inc.1$30
Sunovion Pharmaceuticals Inc.5$30
Amneal Pharmaceuticals LLC2$30
Biohaven Pharmaceuticals, Inc.2$30
Clarus Therapeutics Inc.2$29
Paratek Pharmaceuticals, Inc.2$29
Sumitomo Pharma America, Inc.2$28
Currax Pharmaceuticals LLC2$24
Daiichi Sankyo Inc.1$21
Phathom Pharmaceuticals, Inc.1$20
Avion Pharmaceuticals1$20
Xeris Pharmaceuticals, Inc.1$19
Scilex Pharmaceuticals Inc.1$19
Dermira, Inc.1$18
Idorsia Pharmaceuticals US Inc1$18
Collegium Pharmaceutical, Inc.1$16

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,525 in reported general payments places this provider in the 90th percentile of 3,983 family medicine providers in Ohio.

See all family medicine providers in Ohio

Medicare billing

Part B allowed, 2024
$144,863
Medicare patients
380
Services billed
2,530

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban279$162,998
JanuviaSitagliptin Phosphate46$55,257
FarxigaDapagliflozin Propanediol63$50,834
OxycontinOxycodone Hcl14$47,486
XareltoRivaroxaban64$46,131
OzempicSemaglutide34$42,610
JardianceEmpagliflozin56$39,035
MounjaroTirzepatide35$37,065
Trelegy ElliptaFluticasone/Umeclidin/Vilanter42$34,332
RexultiBrexpiprazole22$32,798
EntrestoSacubitril/Valsartan38$22,181
InvokanaCanagliflozin21$20,473
GemtesaVibegron45$13,837
Lantus SolostarInsulin Glargine,hum.Rec.Anlog81$11,023
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog15$10,783

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$330$162,998279 claims
Johnson & JohnsonXarelto, Invokana$235$66,60485 claims
AstraZenecaFarxiga, Breztri Aerosphere$746$60,70878 claims
MerckJanuvia$587$55,25746 claims
Novo NordiskOzempic$420$42,61034 claims
Boehringer IngelheimJardiance$253$39,03556 claims
Lilly USA, LLCMounjaro$106$37,06535 claims
GSKTrelegy Ellipta$61$34,33242 claims
Otsuka America Pharmaceutical, Inc.Rexulti$91$32,79822 claims
NovartisEntresto$78$22,18138 claims
Sumitomo Pharma America, Inc.Gemtesa$28$13,83745 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$30$6,468684 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,983 family medicine providers in Ohio.

Other family medicine in Poland

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →